Newly proposed candidate Zika virus vaccines might or might not succeed in raising safe, effective, and durable protection against human Zika virus infections or syndromes. Analyses of a clinically tested and licensed dengue vaccine that failed to protect seronegative individuals from breakthrough or enhanced dengue infections suggest that poor T-cell immunity might have contributed to protection failure. Because of the similarity of Zika and dengue viruses, an analogous unwanted outcome might occur with some Zika virus vaccine designs. A successful Zika virus vaccine requires challenge experiments that are done at long intervals after immunisation and that identify protection as the absence of viraemia and the absence of an anamnestic antibody response. T-cell immunity might be an essential component of safe, efficacious, and durable Zika virus vaccines.
Copyright © 2017 Elsevier Ltd. All rights reserved.